NAGE Niagen Bioscience, Inc.
Legal ·
Niagen and its ChromaDex subsidiary are sued in two consumer class actions and a Thorne patent case. A Federal Circuit ruling on a $9.2 million fee award to Elysium is pending.
Canaccord Genuity and Roth Capital Partners are the sales agents under a June 26, 2026 agreement, for a 3% commission. The supplement puts net tangible book value at $0.97 a share against a $3.37 reference price.
The board lifted the program from $10 million. The company had repurchased approximately $2.6 million of stock through March 17, 2026.
B. Riley Securities is removed from the program. Raymond James and Roth Capital Partners will continue as the sales agents.
Niagen Bioscience, formerly ChromaDex, describes itself as a global bioscience company dedicated to promoting healthy aging. Its research centers on nicotinamide adenine dinucleotide (NAD+), a coenzyme that regulates cellular metabolism. The company commercializes Niagen, a proprietary form of nicotinamide riboside chloride, which it introduced as a food-grade dietary and food ingredient in 2013. In 2017 it launched Tru Niagen, a finished dietary supplement sold directly to consumers. In 2024 it launched Niagen Plus products featuring pharmaceutical-grade Niagen, which it supplies to U.S. FDA-registered 503B outsourcing facilities and to compound pharmacies abroad that prepare Niagen intravenous and injectable formulations for use with a prescription. The text says food-grade Niagen is authorized for human consumption as a dietary supplement and is generally recognized as safe, and that more than 525 published human clinical studies relate to NAD+. The company changed its name to Niagen Bioscience, and its Nasdaq ticker to NAGE, effective March 19, 2025.
| Product or program | What it is | Stage |
|---|---|---|
| Niagen | Food-grade nicotinamide riboside ingredient for dietary and food use | |
| Tru Niagen | Finished dietary supplement sold directly to consumers | |
| Niagen Plus | Products featuring pharmaceutical-grade Niagen |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $129.4 million | $99.6 million |
| Research and development | $6.3 million | $6.0 million |
| Net income (loss) | $17.4 million | $8.6 million |
| Cash from operations | $13.5 million | $12.1 million |
| Cash and equivalents | $64.8 million | $44.5 million |
Our latest story on this, dated Aug 4, 2026: "Niagen Bioscience details consumer class actions, Thorne suit and Elysium fee appeal". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Nov 21, 2024: "ChromaDex (now Niagen Bioscience) adds Roth Capital to at-the-market program". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 19, 2026: "Niagen Bioscience raises share buyback authorization to $20 million". The story links the filing or release it is based on. Read the story.
Niagen Bioscience, Inc. trades under the ticker NAGE on NASDAQ.
Niagen Bioscience, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:OCD1; LS:A2AG5N; LSX:A2AG5N.
The SEC Central Index Key (CIK) for Niagen Bioscience, Inc. is 1386570. Its filings are on SEC EDGAR.
79,126,002 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-04.
Our directory records Niagen Bioscience, Inc. under United States.
Our directory classifies Niagen Bioscience, Inc. as: Mixed biopharma / other operations. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Niagen Bioscience, Inc. is US1710774076.
aibio.space lists Niagen Bioscience, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Niagen Bioscience, formerly ChromaDex, describes itself as a global bioscience company dedicated to promoting healthy aging. Its research centers on nicotinamide adenine dinucleotide (NAD+), a coenzyme that regulates cellular metabolism.
Niagen: Food-grade nicotinamide riboside ingredient for dietary and food use
Tru Niagen: Finished dietary supplement sold directly to consumers
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Announced a share repurchase program. SEC Form 8-K (Items 8.01,9.01). Source
Announced a share repurchase program. SEC Form 8-K (Items 8.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio